论文部分内容阅读
目的探讨吡柔比星(THP)膀胱粘膜下浸润注射加单次腔内灌注预防浅表性膀胱癌术后复发的临床效果。方法浅表性膀胱癌29例,其中Ta 6例、T123例(G19例、G211例、G33例)均行膀胱部分切除术,术中采用1 mg/ml浓度的THP多中心膀胱黏膜下浸润注射,总量20 mg,术后6 h内腔内灌注THP 40 mg,保留半小时。术后随访2~5年。结果29例患者术后1、2、3年无瘤生存率分别为100%、96.5%、86.2%,总复发率13.8%(4/29)。术后早期并发症主要为血尿和膀胱刺激症状。膀胱局部毒性反应率为31%(9/29),无全身性毒性反应。结论THP术中多中心膀胱黏膜下浸润注射加单次腔内灌注预防浅表性膀胱癌术后效果良好,费用相对较低,毒副作用小。
Objective To investigate the clinical effect of intravesical intratracheal instillation of pirarubicin (THP) and single intraluminal perfusion to prevent postoperative recurrence of superficial bladder cancer. Methods Twenty-nine patients with superficial bladder cancer were included. Among them, 6 cases of Ta, T123 cases (G19, G211, G33) underwent resection of the bladder. Intraoperative submucosal infiltration of 1 mg / ml THP , The total amount of 20 mg, 6 h after intra-arterial infusion of THP 40 mg, retained for half an hour. Follow-up 2 to 5 years after operation. Results The tumor-free survival rates at 1, 2 and 3 years after operation in the 29 patients were 100%, 96.5% and 86.2%, respectively, with a total recurrence rate of 13.8% (4/29). Early postoperative complications mainly hematuria and bladder irritation. Bladder local toxicity response rate was 31% (9/29), no systemic toxicity. Conclusions Multi-center bladder submucosal infiltration in THP surgery and single intraluminal perfusion to prevent superficial bladder cancer have good effect, relatively low cost and little toxic side effects.